Ieong Chengcheng, Yang Hong, Ma Junpeng, Lai Wenli
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University.
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Medicine (Baltimore). 2020 Feb;99(9):e18497. doi: 10.1097/MD.0000000000018497.
The aim of this meta-analysis was to systematically evaluate the prognostic significance of X-linked inhibitor of apoptosis protein (XIAP) in patients with gastrointestinal tract (GIT) cancers.
PubMed, Web of Science, EMBASE, Cochrane Library and China National Knowledge Infrastructure were searched for potentially eligible literature. The baseline characteristics and relevant data were extracted. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to assess the prognostic role of XIAP in patients with GIT cancers.
Twelve studies with 2,477 patients were included. The pooled HRs of higher expression of XIAP for overall survival (OS) and recurrence free survival (RFS) in patients with GIT cancers were 1.64 (95% CI, 1.27-2.13) and 1.06 (95% CI, 0.96-1.16), respectively. Subgroup analysis and sensitivity analysis were also performed. No significant publication bias was found.
Our results suggested that XIAP could be a prognostic marker for OS but not RFS in patients with GIT cancers. Higher expression of XIAP was related to poorer OS. These findings may help evaluate the prognosis of patients and assist future research on novel therapeutic strategies of GIT cancers by targeting XIAP. However, more well-designed studies are warranted to verify the results.
本荟萃分析的目的是系统评估X连锁凋亡抑制蛋白(XIAP)在胃肠道(GIT)癌症患者中的预后意义。
检索PubMed、科学网、EMBASE、Cochrane图书馆和中国知网,查找可能符合条件的文献。提取基线特征和相关数据。估计风险比(HRs)和95%置信区间(CIs),以评估XIAP在GIT癌症患者中的预后作用。
纳入12项研究,共2477例患者。GIT癌症患者中XIAP高表达对总生存期(OS)和无复发生存期(RFS)的合并HR分别为1.64(95%CI,1.27 - 2.13)和1.06(95%CI,0.96 - 1.16)。还进行了亚组分析和敏感性分析。未发现明显的发表偏倚。
我们的结果表明,XIAP可能是GIT癌症患者OS的预后标志物,但不是RFS的预后标志物。XIAP高表达与较差的OS相关。这些发现可能有助于评估患者的预后,并通过靶向XIAP协助未来对GIT癌症新治疗策略的研究。然而,需要更多设计良好的研究来验证结果。